Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
25.21 USD | +3.57% | +30.88% | +17.74% |
Apr. 16 | Leerink Partners Starts AnaptysBio With Outperform Rating, $47 Price Target | MT |
Apr. 11 | Wells Fargo Initiates AnaptysBio With Overweight Rating, $56 Price Target | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+17.74% | 665M | |
-2.72% | 102B | |
+2.21% | 96.09B | |
+2.13% | 22.28B | |
-17.09% | 21.4B | |
-8.79% | 18.14B | |
-39.98% | 17.02B | |
-13.94% | 16.09B | |
+6.12% | 13.83B | |
+32.06% | 11.97B |
- Stock Market
- Equities
- ANAB Stock
- News AnaptysBio, Inc.
- JPMorgan Upgrades AnaptysBio to Neutral From Underweight, Trims Price Target to $30 From $31